Skip to content
value.today
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc.

Total raised
$116 M
2 rounds on record
Latest round
$100 M
Nov 2021
First round on record
Jan 2021
Today
Went public
See the company page

Acrivon Therapeutics, Inc. is listed today as Acrivon Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Acrivon Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$100 MNo. 2$50 to $250 million

Acrivon Therapeutics, Inc.: Raise no. 2, Nov 2021

Investors in this round

13 investors had bought by the notice of Nov 23, 2021: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Devroe · Executive Officer
  • Erick Gamelin · Executive Officer
  • Kristina Masson · Executive Officer, Director
  • Peter Blume-Jensen · Executive Officer, Director
  • Derek DiRocco · Director
  • Marcin Czernik · Director
  • Sharon Shacham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Blume-Jensen, President. Newest notice filed Nov 23, 2021. Read the notice at the SEC.

equitySEC
Jan 2021$16 MNo. 1$10 to $50 million

Acrivon Therapeutics, Inc.: Raise no. 1, Jan 2021

Investors in this round

2 investors had bought by the notice of Feb 12, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Devroe · Executive Officer
  • Kristina Masson · Executive Officer, Director
  • Peter Blume-Jensen · Executive Officer, Director
  • Marcin Czernik · Director
  • Sharon Shacham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Blume-Jensen, President. Newest notice filed Feb 12, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Acrivon Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2021).

    SEC Form D · Nov 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2021

Products and services#

No products or services of Acrivon Therapeutics, Inc. are on record.

Investors#

No investor of Acrivon Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Acrivon Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Acrivon Therapeutics, Inc.
NameRoleNamed in
Eric DevroeExecutive officerNov 2021
Erick GamelinExecutive officerNov 2021
Kristina MassonExecutive officerNov 2021
Peter Blume-JensenExecutive officerNov 2021
Derek DiRoccoDirectorNov 2021
Kristina MassonDirectorNov 2021
Marcin CzernikDirectorNov 2021
Peter Blume-JensenDirectorNov 2021
Sharon ShachamDirectorNov 2021

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.